About ALK-Abello
ALK-Abello is a company based in Hørsholm (Denmark) founded in 1923.. The company has 2,750 employees as of December 31, 2024. ALK-Abello has completed 2 acquisitions, including Bio-Medical Services and Crystal Laboratory. ALK-Abello offers products and services including Allergy Vaccines, Diagnostics, and Consumer Healthcare. ALK-Abello operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Dren Bio and Vividion Therapeutics, among others.
- Headquarter Hørsholm, Denmark
- Employees 2750 as on 31 Dec, 2024
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Alk-Abello A/S Class B
-
Annual Revenue
$771.74 M (USD)14.78as on Dec 31, 2024
-
Net Profit
$113.53 M (USD)67.7as on Dec 31, 2024
-
EBITDA
$189.45 M (USD)49.61as on Dec 31, 2024
-
Latest Funding Round
$110.72 M (USD), Post-IPO
Dec 08, 2017
- Investors
-
Employee Count
2750
as on Dec 31, 2024
-
Investments & Acquisitions
Bio-Medical Services
& 1 more
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of ALK-Abello
ALK-Abello is a publicly listed company on the OMXCOP with ticker symbol ALK_B in Denmark, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of ALK-Abello
ALK-Abello offers a comprehensive portfolio of products and services, including Allergy Vaccines, Diagnostics, and Consumer Healthcare. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Vaccines for treating allergies like pollen and dust mites.
Tools for diagnosing various types of allergies.
Products for managing everyday allergy symptoms.
Unlock access to complete
Unlock access to complete
Funding Insights of ALK-Abello
- Total Funding Total Funding
- Total Rounds 2
- Last Round Post-IPO — $110.7M
-
First Round
First Round
(03 Jan 2007)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2017 | Amount | Post-IPO - ALK-Abello | Valuation |
investors |
|
| Jan, 2007 | Amount | Post-IPO - ALK-Abello | Valuation |
investors |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in ALK-Abello
ALK-Abello has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Merck. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Pharmaceutical products are manufactured and marketed worldwide.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by ALK-Abello
ALK-Abello has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Bio-Medical Services and Crystal Laboratory. These strategic investments and acquisitions demonstrate the company's commitment to growth through portfolio expansion, market consolidation, technology integration, and strategic partnerships that enhance competitive positioning and drive long-term value creation.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Veterinary health products are provided by Bio-Medical Services.
|
1999 | ||||
|
Manufacturer of allergy medicines
|
1968 |
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
OVO is recognized as a smart digital payment application.
|
2017 | ||||
|
Bionic investment advisor platform
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 |
Financial Statements - ALK-Abello
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Alk-Abello Comparisons
Competitors of ALK-Abello
ALK-Abello operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Dren Bio and Vividion Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| domain | founded_year | HQ Location |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| domain | founded_year | HQ Location |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies are developed for cancer, autoimmune, and serious diseases.
|
|
| domain | founded_year | HQ Location |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| domain | founded_year | HQ Location |
RNA-editing technologies are provided for precision medicine applications.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Alk-Abello
Frequently Asked Questions about ALK-Abello
When was ALK-Abello founded?
ALK-Abello was founded in 1923 and raised its 1st funding round 84 years after it was founded.
Where is ALK-Abello located?
ALK-Abello is headquartered in Hørsholm, Denmark.
Who is the current CEO of ALK-Abello?
Carsten Hellmann is the current CEO of ALK-Abello.
How many employees does ALK-Abello have?
As of Dec 31, 2024, the latest employee count at ALK-Abello is 2,750.
What is the annual revenue of ALK-Abello?
Annual revenue of ALK-Abello is $771.74M as on Dec 31, 2024.
What does ALK-Abello do?
ALK is a Danish, Public Biopharma company developing allergy immunotherapies including injections (emergency) and sublingual tablets. As on Nov 2016, they are in Phase III trials for sublingual allergy tablets for house dust mite, Japanese cedar and tree pollen. They have already marketed sublingual tablets for grass and ragweed. They also manufacture adrenaline auto-injections for anaphylaxis.
Who are the top competitors of ALK-Abello?
ALK-Abello's top competitors include Sutro Biopharma, Avidity Biosciences and Antheia.
What products or services does ALK-Abello offer?
ALK-Abello offers Allergy Vaccines, Diagnostics, and Consumer Healthcare.
Is ALK-Abello publicly traded?
Yes, ALK-Abello is publicly traded on OMXCOP under the ticker symbol ALK_B.
How many acquisitions has ALK-Abello made?
ALK-Abello has made 2 acquisitions, including Bio-Medical Services, and Crystal Laboratory.
Who are ALK-Abello's investors?
ALK-Abello has 1 investor. Key investors include Merck.
What is ALK-Abello's ticker symbol?
The ticker symbol of ALK-Abello is ALK_B on OMXCOP.
Book a demo & talk to our team
Share a few details and we’ll reach out to schedule a session.